- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03913754
Psycho-social Consequences of Systemic Lupus Erythematosus
Psychosocial Consequences of Systemic Lupus Erythematosus: a Study of Patients and Their Spouses Psy-LUP Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Systemic lupus erythematosus (SLE) is a rare chronic autoimmune disease (1/2000 inhabitants) that evolves in periods of recurrent remissions. Sufferers are most often young women of childbearing age. SLE affects the life of a couple like family life (financial, emotional, relational or sexual conditions of the couple). In addition, the disease and its treatments can hinder the possibility of building a family project (pregnancy).
The purpose of the Psy-LUP study is to study the impact of SLE on the social participation of patients, that is to say on their ability to get involved in different areas of daily life. These repercussions could be all the more important as lupus disease is active and complicated by severe diseases such as kidney disease. We want to study how sick people and their loved ones (spouse in particular) think about lupus disease, how it fits into their life history, how people have adapted to this disease, and how it affects their lives. could have on their social participation, their social support, their life of couple. The Psy-LUP study will be carried out in different care services, and by telephone interviews at home, with two main axes: (1) a study by questionnaire with patients (n = 100); (2) a qualitative study through research interviews with patients (n = 40) and their spouses (n = 20). The realization of this project will allow us to evaluate and understand the impact of SLE on the life of the couple and its relational and affective components. In addition, the Psy-LUP study will describe the representations that sick people and their relatives have of lupus disease. All the data collected will make it possible to target interventions with 1) patients and their relatives, in terms of therapeutic education, psychosocial support, support groups (associations); 2) caregivers caring for people with SLE, so that they can integrate the issues of the patient's experience in their care practice and their reflection on therapeutic strategies.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Marseille, France, 13000
- ASSITANCE PUBLIQUE HOPITAUX DE MARSEILLE
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age> 18 years
- Presenting an LES according to ACR or SLICC criteria
- Being followed in Marseille in Nephrology or Internal Medicine as part of the Competence Center Lupus PACA
- Having agreed to participate in the study after information
Exclusion Criteria:
- Minor person
- Person deprived of liberty
- Person not affiliated to a social security scheme
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Lupus Patients with kidneys failure
Assessment of quality of life on everydays life trough questionnare
|
It will be necessary to take into account the psychosocial experience of the disease [47] and to allow a narrative exploration of this experience and its psycho-social consequences both for the patients and their spouses (ie the experiential dimension of the disease in connection with the life trajectory, the life of a couple, elaborate representations concerning the disease).
The purpose of this approach is not only to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inclusion in the socio-cultural condition of the patients, but also to allow an analysis of the inscription. of the disease in the relationship and its implications (relational, affective, sexual) and its impact on the possibilities of social participation.
|
|
Lupus Patients without kidneys failure
Assessment of quality of life on everydays life trough questionnare
|
It will be necessary to take into account the psychosocial experience of the disease [47] and to allow a narrative exploration of this experience and its psycho-social consequences both for the patients and their spouses (ie the experiential dimension of the disease in connection with the life trajectory, the life of a couple, elaborate representations concerning the disease).
The purpose of this approach is not only to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inclusion in the socio-cultural condition of the patients, but also to allow an analysis of the inscription. of the disease in the relationship and its implications (relational, affective, sexual) and its impact on the possibilities of social participation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the physical, psychological and social impact of chronic diseases
Time Frame: 12 months
|
Quality of life scale Short Study Form-36 (SF-36)
|
12 months
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Aim MA, Queyrel V, Tieulie N, Chiche L, Faraut J, Manet C, Schleinitz N, Harle JR, Jourde-Chiche N, Dany L. Importance of temporality and context in relation to life habit restrictions among patients with systemic lupus erythematosus: A psychosocial qualitative study. Lupus. 2022 Oct;31(12):1423-1433. doi: 10.1177/09612033221115966. Epub 2022 Aug 2.
- Manet C, Aim MA, Queyrel V, Faraut J, Costedoat-Chalumeau N, Daugas E, Hachulla E, Harle JR, Huart A, Hummel A, Kaplanski G, Mazodier K, Mancini J, Sarrot-Reynauld F, Schleinitz N, Swiader L, Tieulie N, Manet P, Dany L, Chiche L, Jourde-Chiche N. Determinants of social participation in patients living with systemic lupus erythematosus: the Psy-LUP multicentre study. RMD Open. 2025 Jun 25;11(2):e005661. doi: 10.1136/rmdopen-2025-005661.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-29
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lupus Erythematosus
-
BiogenRecruitingSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusUnited States, Japan, Taiwan, Belgium, Argentina, Chile, Ukraine, China, Spain, Canada, Bulgaria, Italy, Hungary, Serbia, Poland, United Kingdom, France, Brazil, Philippines, Switzerland, Saudi Arabia, Sweden, Germany, Mexico, Puerto Rico, Portug... and more
-
BiogenEnrolling by invitationSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusUnited States, Brazil, Spain, Taiwan, Canada, France, Germany, Japan, Italy, Colombia, United Kingdom, Serbia, Chile, Philippines, Bulgaria, China, Sweden, Switzerland, Mexico, South Korea, Argentina, Hungary, Slovakia, Poland, Portugal
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Immunovant Sciences GmbHActive, not recruitingSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusSerbia, United States, Argentina, Bulgaria, Canada, Chile, Georgia, Germany, Greece, Poland, Puerto Rico, Spain, United Kingdom
-
Florida Academic Dermatology CentersUnknownDiscoid Lupus Erythematosus (DLE)United States
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyRecruitingSystemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)United States
-
Bristol-Myers SquibbActive, not recruitingLupus Erythematosus, Discoid | Lupus Erythematosus, Subacute CutaneousMexico, Australia, United States, Argentina, France, Germany, Poland, Taiwan
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyNot yet recruitingCutaneous Lupus Erythematosus | Systematic Lupus ErythematosusGermany
-
University of RochesterIncyte CorporationCompletedDiscoid Lupus ErythematosusUnited States
-
Massachusetts General HospitalNovartisWithdrawnDiscoid Lupus ErythematosusUnited States
Clinical Trials on Psycho-social consequences of lupus erythematosus
-
Chung Shan Medical UniversityCompleted
-
Sohag UniversityNot yet recruitingSystemic Lupus Erythematosus (SLE)
-
Yale UniversityGlenn Memorial FundTerminated
-
National Institute of Allergy and Infectious Diseases...TerminatedHepatic Steatosis | Cardiac SteatosisUnited States
-
PfizerCompletedOveractive BladderCanada, United States, Costa Rica, Hungary, Slovakia, Spain, Colombia, India, Russian Federation, Ireland, Korea, Republic of, Germany, Sweden, Poland, Bulgaria, Estonia, Brazil, Greece, Latvia, Lithuania, Malaysia, Romania, Singapore, South Africa and more
-
Rambam Health Care CampusUnknownUrinary Bladder, OveractiveIsrael
-
Novartis PharmaceuticalsCompletedEssential HypertensionUnited States
-
Loewenstein HospitalTel Aviv University; Wingate InstituteRecruiting
-
Nina BhardwajMemorial Sloan Kettering Cancer Center; NYU Langone Health; Ludwig Institute... and other collaboratorsCompleted
-
Phoenix Children's HospitalTerminatedComplicated Appendicitis | Perforated AppendicitisUnited States